Dosage Information Please consult your physician or pharmacist or refer to product package
A triple combination targeting epigenetic dysregulation and apoptotic resistance, comprising iadademstat (LSD1 inhibitor), azacitidine (a hypomethylating agent), and venetoclax (a BCL-2 inhibitor), is under investigation in a phase I trial for acute myeloid leukemia (NCT06357182)
doi: 10.3389/fendo.2024.1358404 Received 19 December 2023 Accepted 15 February 2024 Published 05 March 2024 Volume 15 - 2024 Edited by Chen Liu, University of Texas Southwestern Medical Center, United States Reviewed by Surbhi Gahlot, University of Texas Southwestern Medical Center, United States Carlos Manuel Zapata-Martn del Campo, National Institute of Cardiology Ignacio Chavez, Mexico Updates Copyright 2024 Raij and Raij
Certificate of Analysis per product on request Certifications: ISO 9001-certified facilities plus GMP/cGMP manufacturing Location & shipping: US peptide sites in Gardner, MA, and Louisville, KY
Week 48 What you may notice: Clear improvements in body composition
How it works: Tirzepatide activates both GIP and GLP-1 receptors simultaneously
